[go: up one dir, main page]

PE20021100A1 - Compuestos de isoxazolona como inhibidores de citoquinas - Google Patents

Compuestos de isoxazolona como inhibidores de citoquinas

Info

Publication number
PE20021100A1
PE20021100A1 PE2002000440A PE2002000440A PE20021100A1 PE 20021100 A1 PE20021100 A1 PE 20021100A1 PE 2002000440 A PE2002000440 A PE 2002000440A PE 2002000440 A PE2002000440 A PE 2002000440A PE 20021100 A1 PE20021100 A1 PE 20021100A1
Authority
PE
Peru
Prior art keywords
alkinyl
alkenyl
alkyl
isoxazolone
cytokine inhibitors
Prior art date
Application number
PE2002000440A
Other languages
English (en)
Inventor
Michael Philip Clark
Biswanath De
Joshua Spector Tullis
Steven Karl Laughlin
Michael George Natchus
Jane Far-Jine Djung
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20021100A1 publication Critical patent/PE20021100A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERA A UN COMPUESTO DE ISOXAZOLONA DE FORMULA I DONDE CADA R1 ES ALQUILO, ALQUENILO, ALQUINILO, HETEROALQUILO, ENTRE OTROS; m ES 0-5; Q ES EL GRUPO a, b; R2 ES H, ALQUILO, ALQUENILO, ALQUINILO, HETEROALQUILO, HETEROALQUENILO, ENTRE OTROS; R3 ES H, ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; X ES CR3, N; Y ES CR2, N; Y ES CR2, N; Z ES NR4, O, S; A ES C(O), N-G-; B ES C(O), N-G; SIEMPRE QUE UNO Y SOLAMENTE UNO DE A O B ES C(O); G ES H, ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, CICLOALQUENILO, ENTRE OTROS; R4 ES H, ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; R5 ES H, ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS DE 2-ETOXIMETIL-4-(4-FLUOROFENIL)-3-PIRIDIN-4-IL-2H-ISOXAZOL-5-ONA, 4-(4-FLUOROFENIL)-2-METIL-3-PIRIDIN-4-IL-2H-ISOXAZOL-5-ONA, ENTRE OTROS. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LAS CITOQUINAS Y SON UTILES EN EL TRATAMIENTO DE ARTRITIS, OSTEOARTRITIS, DIABETES
PE2002000440A 2001-05-24 2002-05-24 Compuestos de isoxazolona como inhibidores de citoquinas PE20021100A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29388901P 2001-05-24 2001-05-24

Publications (1)

Publication Number Publication Date
PE20021100A1 true PE20021100A1 (es) 2003-02-19

Family

ID=23130995

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000440A PE20021100A1 (es) 2001-05-24 2002-05-24 Compuestos de isoxazolona como inhibidores de citoquinas

Country Status (6)

Country Link
US (2) US6790846B2 (es)
EP (1) EP1392299A1 (es)
CN (1) CN1511034A (es)
CA (1) CA2446801A1 (es)
PE (1) PE20021100A1 (es)
WO (1) WO2002094266A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
WO2016041138A1 (en) 2014-09-16 2016-03-24 The Procter & Gamble Company Zinc fluorescent probe
SI3300500T1 (sl) 2015-05-20 2020-07-31 Amgen Inc. Triazolni agonisti receptorja APJ
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
DE69433501T2 (de) 1993-11-08 2004-11-04 Smithkline Beecham Corp. Oxazole zur behandlung von zytokinvermittelten erkrankungen
AU708883B2 (en) 1996-06-10 1999-08-12 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
JP2002515915A (ja) 1997-06-30 2002-05-28 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 炎症性疾患の治療で有用な２−置換イミダゾール類
US6599910B1 (en) 1998-08-20 2003-07-29 Smithkline Beecham Corporation Substituted triazole compounds
WO2000026209A1 (en) 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
CA2381882C (en) 1999-08-13 2011-01-25 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases

Also Published As

Publication number Publication date
US6790846B2 (en) 2004-09-14
US20030096814A1 (en) 2003-05-22
US6919346B2 (en) 2005-07-19
US20040122025A1 (en) 2004-06-24
WO2002094266A1 (en) 2002-11-28
CA2446801A1 (en) 2002-11-28
EP1392299A1 (en) 2004-03-03
CN1511034A (zh) 2004-07-07

Similar Documents

Publication Publication Date Title
PE20021100A1 (es) Compuestos de isoxazolona como inhibidores de citoquinas
PE20020961A1 (es) Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
ECSP067013A (es) 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4
PE20090238A1 (es) Derivados de pirazol como inhibidores de tirosinquinasas
PE20021089A1 (es) Compuestos de triazol como inhibidores de las citoquinas
AR038717A1 (es) Ciclopropil-azol-carboxamidas
PE20090775A1 (es) Nuevos derivados de biarilo
ECSP066298A (es) Compuestos 1h-pirazol 3,4-disustituidos y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicógeno (gsk-3)
PE20080611A1 (es) Compuestos de azabenzofuranil y metodos de uso
AR023152A1 (es) Compuesto tienopirimidina, procedimiento para producirlo, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dichacomposicion
AR038240A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
PE20030010A1 (es) Triazolopiridinas como inhibidores de quinasas
PE20131197A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
PE20020786A1 (es) Derivados de azaindol antiviral
AR050267A1 (es) Derivados de urea ciclicos sustituidos con heterociclo, su preparacion y su uso farmaceutico como inhibidores de quinasa
AR042668A1 (es) Derivados de fosfonoxi quinazolinas y su uso farmaceutico
AR091405A2 (es) Omega-carboxiaril difenil urea sustituida con fluoro y composiciones farmaceuticas que las contienen
PE20151764A1 (es) Derivados de pirrolo[2,3-d]pirimidina
PE20070051A1 (es) Serin-amidas sustituidas con heteroaroilo
AR049261A1 (es) Insecticidas de antranilamida
CO6160312A2 (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
PE20030977A1 (es) Derivados de sulfonil-piperidin como inhibidores de la gamma secretasa
ECSP045369A (es) Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica
CY1107846T1 (el) Παραγωγα κιναζολινονης χρησιμα ως βανιλλοειδεις ανταγωνιστες

Legal Events

Date Code Title Description
FD Application declared void or lapsed